How can AI reshape the way consumer health products are developed? Dr. Nuzhat Tam-Zaman of Sinoveda Canada Inc. introduces an AI-driven pharmaceutical platform technology (AI-PPT) that moves from computational discovery to biological validation, applying pharmaceutical-level rigour to consumer health. The session will highlight select products, their functions, and the markets they aim to serve.

Dr. Nuzhat Tam-Zaman

Dr. Tam-Zaman is an experienced entrepreneur with a Ph.D. in Pharmaceutical Sciences from the University of Alberta and a demonstrated history in the pharmaceutical industry. She is a strong business development professional, skilled in pharmaceutical and natural health products development, cannabis research, regulatory affairs, biotechnology, and the sales and marketing of natural health products in export markets. She was the Co-Chair of BioAlberta and Co-Chair of JWG or Joint Working Group; an association between Canada and Bangladesh to increase bi-lateral trade between the two countries in the health sector.

Sinoveda Canada Inc.

Sinoveda is transforming drug discovery with AI-PPT, a cutting-edge platform that harnesses the power of AI to optimize natural therapies. Unlike traditional biotech companies, Sinoveda ensures that its drug candidates undergo extensive human validation before entering clinical trials, reducing risk and accelerating approval. Its lead candidate, Cordyva, targets post-viral fatigue, fibromyalgia, and immune-related cognitive dysfunction, addressing a significant unmet medical need. Founded in 2006, Sinoveda is now scaling up with a diverse pipeline in women’s health, eczema, and sleep disorders, poised for global expansion.